Vireo Growth (VREOF) Net Income towards Common Stockholders (2020 - 2026)
Vireo Growth (VREOF) posted Net Income towards Common Stockholders of -$22.5 million for Q1 2026, up 33.39% sequentially from -$33.8 million in Q4 2025, and down 562.98% YoY from $4.9 million in Q1 2025.
Vireo Growth (VREOF) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Vireo Growth has reported Net Income towards Common Stockholders for 7 years, with the latest figure at -$22.5 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 562.98% year-over-year to -$22.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$49.8 million (down 384.51% YoY) and the FY2025 annual result came in at -$81.5 million, down 598.32% from the prior year.
- Net Income towards Common Stockholders advanced to -$22.5 million in Q1 2026 per VREOF's latest filing, from -$33.8 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $4.9 million in Q1 2025 and troughed at -$33.8 million in Q4 2025.
- A 5-year average of -$5.3 million and a median of -$5.7 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders surged 176.72% in 2024, then tumbled 903.06% in 2025.
- Over 5 years, Net Income towards Common Stockholders stood at -$9.3 million in 2022, then jumped by 138.44% to $3.6 million in 2023, then rose by 17.77% to $4.2 million in 2024, then sank by 903.06% to -$33.8 million in 2025, then soared by 33.39% to -$22.5 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$22.5 million, -$33.8 million, and $2.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn | 710.19 Mn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Vireo Growth | 493.25 Mn | 350.95 Mn | 95.30 Mn | -5.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.50 Mn |
| Dec 31, 2025 | -33.78 Mn |
| Sep 30, 2025 | 2.76 Mn |
| Jun 30, 2025 | 3.67 Mn |
| Mar 31, 2025 | 4.86 Mn |
| Dec 31, 2024 | 4.21 Mn |
| Sep 30, 2024 | 4.40 Mn |
| Jun 30, 2024 | 4.06 Mn |
| Mar 31, 2024 | 3.70 Mn |
| Dec 31, 2023 | 3.57 Mn |
| Sep 30, 2023 | -5.73 Mn |
| Jun 30, 2023 | -7.39 Mn |
| Mar 31, 2023 | -8.47 Mn |
| Dec 31, 2022 | -9.29 Mn |
| Sep 30, 2022 | -9.57 Mn |
| Jun 30, 2022 | -6.10 Mn |
| Mar 31, 2022 | -17.68 Mn |
| Dec 31, 2021 | -14.09 Mn |
| Sep 30, 2021 | -6.84 Mn |
| Jun 30, 2021 | -6.99 Mn |